IMpower150 Interim OS Analysis: Atezolizumab + CT ± Bevacizumab vs CT + Bevacizumab in Patients With Untreated Advanced Nonsquamous NSCLC

June 1-5, 2018; Chicago, Illinois
Addition of atezolizumab to carboplatin/paclitaxel + bevacizumab significantly prolonged PFS and OS when given as first-line therapy in advanced nonsquamous NSCLC.
Format: Microsoft PowerPoint (.ppt)
File Size: 321 KB
Released: June 12, 2018

Acknowledgements

Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Astellas
AstraZeneca
Celgene Corporation
Eisai
Genentech
Janssen Therapeutics
Merck & Co., Inc.
Seattle Genetics

Related Content

Downloadable resource: current EGFR-targeted agents for advanced NSCLC with EGFR mutations, including exon 20 insertions, from Clinical Care Options (CCO)

Released: May 24, 2022

Downloadable resource on active research and ongoing clinical trials in EGFR-mutated NSCLC, from Clinical Care Options (CCO)

Released: May 24, 2022

Downloadable resource on best practices for molecular testing of targetable biomarkers in advanced NSCLC (May 2022), from Clinical Care Options (CCO)

Released: May 24, 2022

Clinical Care Options (CCO) commentary: Joel Neal, MD, discusses management of non-small-cell lung cancer (NSCLC) with uncommon EGFR mutations

Joel W. Neal, MD, PhD Released: May 20, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings